Tags : HER2-positive Early Breast Cancer (eBC

Roche Reports Results of Kadcyla (trastuzumab emtansine) in P-III KATHERINE

Shots: The P-III KATHERINE study assessed Kadcyla vs Herceptin (trastuzumab) as an adjuvant therapy for patients with HER2-positive eBC for three years P-III KATHERINE study results: risk of disease recurrence or death 50%; didn’t have breast cancer return (88.3% vs 77.0%); with no new safety issues Kadcyla is an antibody-drug conjugate (ADC) developed for delivering […]Read More